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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to iron 
and contribution to normal cognitive development pursuant to Article 14 of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from IDACE, submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via 
the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was 
asked to deliver an opinion on the scientific substantiation of a health claim related to iron and contribution to 
normal cognitive development. The food constituent, iron, which is the subject of the health claim, is sufficiently 
characterised. Contribution to normal cognitive development is a beneficial physiological effect for infants and 
young children. A claim on iron and cognitive development in children (up to 18 years) has already been 
assessed with a favourable outcome. The Panel notes that the role of iron in normal cognitive development also 
applies to infants and young children (from birth to three years). The Panel concludes that a cause and effect 
relationship has been established between dietary intake of iron and contribution to normal cognitive 
development. The following wording reflects the scientific evidence: “Iron contributes to normal cognitive 
development”. The target population is infants and children up to three years.  
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from IDACE, submitted for authorisation of a health claim pursuant to 
Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel 
on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to iron and contribution to normal cognitive development. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food constituent that is the subject of the health claim is iron, which is a well recognised nutrient 
and is measurable in foods by established methods. The Panel considers that iron is sufficiently 
characterised. 
The claimed effect proposed by the applicant is “important for the cognitive development of infants 
and young children”. The target population proposed by the applicant is “infants and young children 
from birth to three years of age”. The Panel considers that contribution to normal cognitive 
development is a beneficial physiological effect for infants and young children. 
The evidence provided by consensus opinions/reports from authoritative bodies and reviews shows 
that there is consensus on the role of iron in cognitive development and function. Insufficient iron 
intake results in iron deficiency signs and symptoms, including anaemia, impaired psychomotor 
development and impaired cognitive performance. The cognitive deficiency symptoms observed in 
subjects with iron-deficiency anaemia include deficits in attention, perceptual motor speed, memory 
and verbal fluency. 
A claim on iron and cognitive development in children (up to 18 years) has already been assessed by 
the Panel with a favourable outcome. The Panel notes that the role of iron in normal cognitive 
development also applies to infants and young children (from birth to three years).  
The Panel concludes that a cause and effect relationship has been established between dietary intake 
of iron and contribution to normal cognitive development. 
The following wording reflects the scientific evidence: “Iron contributes to normal cognitive 
development”.  
The Panel considers that, in order to bear the claim, follow-on formulae should comply with the 
criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally 
complete foods for special medical purposes intended for use by infants and nutritionally complete 
foods for special medical purposes other than those intended for use by infants should comply with 
the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-
based foods for infants and young children should comply with the criteria of composition of these 
foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young 
children should provide at least 15 % of the reference values for nutrition labelling for foods intended 
for infants and young children as laid down in Directive 2006/125/EC. Such amounts can be easily 
consumed as part of a balanced diet. The target population is infants and children up to three years. 
No Upper Tolerable Intake Level has been set for iron in this age group. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 14/02/2008. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 26/03/2008, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 08/05/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 20/06/2013. 
 During its meeting on 11/07/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to iron and 
contribution to normal cognitive development. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: iron and contribution to normal 
cognitive development. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of iron, a positive assessment of its safety, nor a decision on whether iron is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework 
of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: IDACE (Association of the Food Industries for Particular 
Nutritional Uses of the European Union), 194, rue de Rivoli, 75001, Paris, France. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is iron. 
Health relationship as claimed by the applicant 
According to the applicant, iron is important for the cognitive development of infants and young 
children.  
According to the applicant, insufficient iron intake results in a deficiency condition called anaemia, 
leading to well-documented, potentially irreversible delays in the cognitive development of infants 
and young children, which can in turn be responsible for low performance in cognitive skills. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “with iron, important for 
cognitive development”.  
As equivalent alternative wordings, the applicant has also proposed: “iron/contributes to/is involved 
in/is important for/plays an important role for/is necessary for/participates to/is needed 
for/supports/the development of cognitive system or brain/the normal development of cognitive 
system or brain/the function of cognitive system or brain/the normal function of cognitive system or 
brain”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is infants and young children from birth to three 
years of age. The claim should be used on foods that are exclusively intended for the category of 
infants and young children, and in line with the composition laid down in the specific directives 
(Directive 2006/141/EC; Directive 2006/125/EC; Directive 1999/21/EC). 
According to the applicant, the quantity needed to achieve the claimed effect is: 
 For follow-on formulae, the content in iron should be within the range set in Directive 
2006/141/EC. 
 For dietary foods for special medical purposes, the content in iron should be within the range 
set in Directive 1999/21/EC. 
 For processed cereal-based foods and baby foods, the content in iron should be within the 
range set in Directive 2006/125/EC. 
 For processed cereal-based foods and baby foods, the content in iron should reach at least 
15 % of the Nutrient Reference Values set in Directive 2006/125/EC, i.e. 15 % of 6 mg per 
100 g or 100 ml or per serving, as reconstituted. 
 For foods intended for infants and young children other than follow-on formulae, processed 
cereal-based foods and baby foods, the content in iron should reach at least 15 % of the 
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Nutrient Reference Values set in Directive 2006/141/EC (replacing Directive 91/321/EC), i.e. 
15 % of 8 mg per 100 ml product ready for use. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is iron, which is a well recognised nutrient 
and is measurable in foods by established methods. 
Iron occurs naturally in foods in various forms, principally haem iron derived from haemoglobin and 
myoglobin in flesh foods, and non-haem iron in plants foods (IoM, 2001). Different forms of iron are 
authorised for addition to foods (Annex I of Regulation (EC) No 1925/2006
5
, Annex I of 
Directive 2002/46/EC
6
, Annex III of Directive 2006/141/EC
7
, Annex IV of Directive 2006/125/EC
8
, 
Directive 2001/15/EC
9
). This evaluation applies to iron naturally present in foods and those forms 
authorised for addition to foods (Annex II of Regulation (EC) No 1925/2006, Annex II of 
Directive 2002/46/EC, Annex III of Directive 2006/141/EC, Annex IV of Directive 2006/125/EC, 
Directive 2001/15/EC). 
The Panel considers that the food constituent, iron, which is the subject of the health claim, is 
sufficiently characterised.  
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “important for the cognitive development of infants 
and young children”. The target population proposed by the applicant is “infants and young children 
from birth to three years of age”. 
The Panel considers that contribution to normal cognitive development is a beneficial physiological 
effect for infants and young children. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Medline, Ovid and the Cochrane database, without 
specifying which period was covered. The search terms were “iron deficiency” OR “iron deficiency 
anaemia and psychomotor development” OR “cognitive development” OR “brain in infants and iron 
deficiency anaemia” and/or “psychomotor development in infants”. The applicant identified seven 
human intervention studies, two observational studies and one meta-analysis as being pertinent to the 
health claim. The human intervention studies investigated the effect of iron supplementation on 
mental and/or psychomotor development in iron deficient infants and young children (Aukett et al., 
1986; Walter et al., 1989; Williams et al., 1999; Idjradinata and Pollitt, 1993; Moffatt et al., 1994; 
Lozoff et al., 1996; Morley et al., 1999). The observational studies evaluated the association between 
iron supplementation and the development of the central nervous system in infants and young children 
(Roncagliolo et al., 1998; Algarin et al., 2003). The meta-analysis included randomised controlled 
                                                     
5 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
6 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
7 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33. 
8 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
9 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes 
in foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25. 
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trials which investigated the effect of iron on psychomotor development in iron deficient infants and 
young children (Logan et al., 2001). 
The evidence provided by consensus opinions/reports from authoritative bodies and reviews shows 
that there is consensus on the role of iron in cognitive development and function (Grantham and Ani, 
2001; Hunt, 2005; SACN, 2009; Schulze and Dreyfuss, 2005; WHO, 2003).  
Iron is an essential trace element with important metabolic functions, including oxygen transport, and 
is involved in several redox reactions. Insufficient iron intake results in iron deficiency signs and 
symptoms, including anaemia, impaired psychomotor development and impaired cognitive 
performance (EFSA, 2004). The cognitive deficiency symptoms observed in subjects with iron-
deficiency anaemia include deficits in attention, perceptual motor speed, memory and verbal fluency 
(Malestrom, 2002).  
The Panel has already assessed a claim on iron and cognitive development of children with a 
favourable outcome (EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009). The 
target population was children and adolescents up to 18 years. The Panel notes that the role of iron in 
normal cognitive development also applies to infants and young children (from birth to three years). 
The Panel concludes that a cause and effect relationship has been established between dietary intake 
of iron and contribution to normal cognitive development. 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “Iron contributes to 
normal cognitive development”. 
5. Conditions and restrictions of use  
The Panel considers that, in order to bear the claim: 
 follow-on formulae should comply with the criteria of composition of follow-on formulae as 
laid down in Directive 2006/141/EC; 
 nutritionally complete foods for special medical purposes intended for use by infants and 
nutritionally complete foods for special medical purposes other than those intended for use by 
infants should comply with the criteria of composition of these foods as laid down in 
Directive 1999/21/EC
10
; 
 processed cereal-based foods for infants and young children should comply with the criteria 
of composition of these foods as laid down in Directive 2006/125/EC; 
 other foodstuffs intended for infants and young children should provide at least 15 % of the 
reference values for nutrition labelling for foods intended for infants and young children as 
laid down in Directive 2006/125/EC.  
Such amounts can be easily consumed as part of a balanced diet. The target population is infants and 
children up to three years. No Tolerable Upper Intake Level (UL) has been set for iron (EFSA, 2004). 
                                                     
10 Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes. OJ L 91, 7.4.1999, p. 
29–36. 
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, iron, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect proposed by the applicant is “important for the cognitive development of 
infants and young children”. The target population proposed by the applicant is “infants and 
young children from birth to three years of age”. Contribution to normal cognitive 
development is a beneficial physiological effect for infants and young children. 
 A cause and effect relationship has been established between dietary intake of iron and 
contribution to normal cognitive development. 
 The following wording reflects the scientific evidence: “Iron contributes to normal cognitive 
development”. 
 In order to bear the claim follow-on formulae should comply with the criteria of composition 
of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods 
for special medical purposes intended for use by infants and nutritionally complete foods for 
special medical purposes other than those intended for use by infants should comply with the 
criteria of composition of these foods as laid down in Directive 1999/21/EC; processed 
cereal-based foods for infants and young children should comply with the criteria of 
composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended 
for infants and young children should provide at least 15 % of the reference values for 
nutrition labelling for foods intended for infants and young children as laid down in Directive 
2006/125/EC. Such amounts can be easily consumed as part of a balanced diet. The target 
population is infants and children up to three years. No UL has been set for iron in this age 
group. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on iron and contribution to normal cognitive development pursuant to 
Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0119_FR). February 2008. Submitted 
by IDACE. 
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GLOSSARY/ABBREVIATIONS 
UL  Tolerable Upper Intake Level 
 
 
